Corona Remedies (NSE:CORONA) Total Receivables: ₹1,462 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:CORONA Corona Remedies Ltd NSE:CORONA
18 GF Score
Price ₹2,098.80
! 3 Warning Signs
View Full Analysis

What is Corona Remedies Total Receivables?

Corona Remedies NSE:CORONA +0.37% 18 Total Receivables is ₹1,462 Mil as of Mar. 2026. GuruFocus rates NSE:CORONA with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

Corona Remedies's Total Receivables for the quarter that ended in Mar. 2026 was ₹1,462 Mil.

Corona Remedies Total Receivables Related Terms

Corona Remedies Total Receivables Historical Data

* Premium members only.

The historical data trend for Corona Remedies's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corona Remedies Total Receivables Chart

Corona Remedies Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Total Receivables
876.96 1,007.10 1,218.60 1,461.80

Corona Remedies Quarterly Data
Mar23 Mar24 Dec24 Mar25 Jun25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial 0.00 1,218.60 1,617.93 0.00 1,461.80
NSE:CORONA
18GF Score
Corona Remedies Ltd NSE:CORONA
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corona Remedies Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ₹1,462 Mil mean?
Corona Remedies (NSE:CORONA) has a Total Receivables of ₹1,462 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Corona Remedies and its competitors.
Is Corona Remedies' Total Receivables too high?
Corona Remedies' current Total Receivables is ₹1,462 Mil. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' Total Receivables compare to LLY and JNJ?
Corona Remedies' Total Receivables of ₹1,462 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Corona Remedies and its competitors. Corona Remedies's current Total Receivables is ₹1,462 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current Total Receivables of ₹1,462 Mil. The current Total Receivables is ₹1,462 Mil. Corona Remedies' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current Total Receivables is ₹1,462 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corona Remedies Business Description

Other Exchanges 544644:India
Address S. G. Highway, CORONA House, C - Mondeal Business Park, Near Gurudwara, Thaltej, Ahmedabad, GJ, IND, 380 059
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score

Get the complete analysis for NSE:CORONA

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,098.80
Price